A Phase I-II Study of the Combination of Bendamustine and Pomalidomide with Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma.

被引：1
|
作者：
Gasparetto, Cristina [1 ]
Green, Michael [2 ]
Srinivasan, Anandgopal [3 ]
Kang, Yubin [4 ]
Rizzieri, David A. [2 ]
Decastro, Carlos [1 ]
Diehl, Louis F. [1 ]
Beaven, Anne [1 ]
Li, Zighuo [1 ]
Rao, Arati V. [5 ,6 ]
Garrett, Anderson [1 ]
Tuchman, Sascha [7 ]
Long, Gwynn D. [1 ]
机构：
[1] Duke Univ, Med Ctr, Durham, NC USA
[2] Duke Univ, Med Ctr, Dept Med, Div Hematol Malignancies & Cellular Therapy, Durham, NC 27710 USA
[3] Univ Cambridge, Sch Clin Med, Cambridge, England
[4] Duke Univ, Med, Durham, NC USA
[5] Duke Univ, Div Cellular Therapy, Med, Durham, NC USA
[6] Duke Univ, Duke Canc Inst, Durham, NC USA
[7] Duke Univ, Durham, NC USA
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
10.1182/blood.V126.23.1857.1857
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma
    Amrita Krishnan
    Prashant Kapoor
    Joycelynne M. Palmer
    Ni-Chun Tsai
    Shaji Kumar
    Sagar Lonial
    Myo Htut
    Chatchada Karanes
    Nitya Nathwani
    Michael Rosenzweig
    Firoozeh Sahebi
    George Somlo
    Lupe Duarte
    James F. Sanchez
    Daniel Auclair
    Stephen J. Forman
    Jesus G. Berdeja
    Leukemia, 2018, 32 : 1567 - 1574
  • [32] Pembrolizumab in Combination with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM)
    Badros, Ashraf Z.
    Hyjek, Elizabeth
    Ma, Ning
    Lesokhin, Alexander M.
    Rapoport, Aaron P.
    Kocoglu, Mehmet H.
    Lederer, Emily
    Philip, Sunita
    Lesho, Patricia
    Johnson, Ashlee
    Dell, Cameron
    Goloubeva, Olga
    Singh, Zeba
    BLOOD, 2016, 128 (22)
  • [33] Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma
    Krishnan, Amrita
    Kapoor, Prashant
    Palmer, Joycelynne M.
    Tsai, Ni-Chun
    Kumar, Shaji
    Lonial, Sagar
    Htut, Myo
    Karanes, Chatchada
    Nathwani, Nitya
    Rosenzweig, Michael
    Sahebi, Firoozeh
    Somlo, George
    Duarte, Lupe
    Sanchez, James F.
    Auclair, Daniel
    Forman, Stephen J.
    Berdeja, Jesus G.
    LEUKEMIA, 2018, 32 (07) : 1567 - 1574
  • [34] BENDAMUSTINE, BORTEZOMIB AND DEXAMETHASONE (BVD) COMBINATION FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: AN INTERIM ANALYSIS OF A PHASE II STUDY
    Offidani, M.
    Corvatta, L.
    Caraffa, P.
    Liberati, A. M.
    Alesiani, F.
    Brunori, M.
    di Toritto, T. Caravita
    Gentili, S.
    Attolico, I.
    Mele, A.
    Pulini, S.
    Ballanti, S.
    Galimberti, S.
    Gozzetti, A.
    Coppetelli, U.
    Ledda, A.
    Leoni, P.
    HAEMATOLOGICA, 2012, 97 : 353 - 353
  • [35] PANORAMA 2: A phase II study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory multiple myeloma.
    Alsina, Melissa
    Schlossman, Robert L.
    Weber, Donna M.
    Coutre, Steven E.
    Lonial, Sagar
    Gasparetto, Cristina
    Warsi, Ghulam
    Ondovik, Michael S.
    Mukhopadhyay, Sutapa
    Paley, Carole S.
    Richardson, Paul Gerard Guy
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [36] Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma
    Yee, Andrew J.
    Laubach, Jacob P.
    Campagnaro, Erica L.
    Lipe, Brea C.
    Nadeem, Omar
    Friedman, Robb S.
    Cole, Craig E.
    O'Donnell, Elizabeth K.
    Bianchi, Giada
    Branagan, Andrew R.
    Schlossman, Robert L.
    Shapiro, Samantha J.
    Harrington, Cynthia C.
    Burke, Jill N.
    Gammon, Marilyn T.
    Lively, Kathleen J.
    Reimonn, Cassandra A.
    Andrade, Danielle X.
    Redd, Robert
    Lohr, Jens G.
    Anderson, Kenneth C.
    Richardson, Paul G.
    Raje, Noopur S.
    BLOOD ADVANCES, 2025, 9 (05) : 1163 - 1170
  • [37] Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma
    Mark, Tomer M.
    Forsberg, Peter A.
    Rossi, Adriana C.
    Pearse, Roger N.
    Pekle, Karen A.
    Perry, Arthur
    Boyer, Angelique
    Tegnestam, Linda
    Jayabalan, David
    Coleman, Morton
    Niesvizky, Ruben
    BLOOD ADVANCES, 2019, 3 (04) : 603 - 611
  • [38] Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma: A phase I study
    Siegel, D. S.
    Weber, D. M.
    Mitsiades, C. S.
    Dimopoulos, M. A.
    Harousseau, J. L.
    Rizvi, S.
    Howe, J.
    Reiser, D.
    Anderson, K. C.
    Richardson, P. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [39] A Phase I Study of Ixazomib in Combination with Panobinostat and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
    Reu, Frederic J.
    Valent, Jason
    Malek, Ehsan
    Sobecks, Ronald M.
    Faiman, Beth M.
    Hamilton, Kimberly
    Elberson, Jamie
    Fada, Sherry
    Liu, Hien K.
    Samaras, Christy
    Smith, Mitchell R.
    BLOOD, 2015, 126 (23)
  • [40] A Phase I Study of Vorinostat in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
    Siegel, David
    Weber, Donna
    Mitsiades, Constantine S.
    Rizvi, Syed
    Garcia-Vargas, Jose
    Howe, Jason
    Reiser, David
    Anderson, Kenneth C.
    Richardson, Paul
    BLOOD, 2008, 112 (11) : 1270 - 1270
12345